home / stock / algs / algs news

ALGS News and Press, Aligos Therapeutics Inc. From 07/27/23

Stock Information
Company Name: Aligos Therapeutics Inc.
Stock Symbol: ALGS
Market: NASDAQ
Website: aligos.com
Menu
ALGS ALGS Quote ALGS Short ALGS News ALGS Articles ALGS Message Board
Get ALGS Alerts

News, Short Squeeze, Breakout and More Instantly...
ALGS - Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023

SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral disea...
ALGS - Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009

- Phase 1 study conduct complete with preliminary data indicating THR-beta agonist ALG-055009 was well-tolerated with a favorable PK profile and dose responsive changes in relevant biomarkers -Upcoming randomized, double blind, placebo-controlled Ph2a study will evaluate the safet...

ALGS - Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks- -Data collectively highlight company’s progress advancing new potentially best-in-class ...

ALGS - Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present se...
ALGS - Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MB...

ALGS - Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal

2023-05-21 09:05:00 ET Summary Shanghai’s LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million (including $55 million upfront) plus royalties on sales. Suzhou Coherent Biopharma closed a Series B+ round...

ALGS - TIGR, APLS and LMFA among pre-market losers

2023-05-16 08:30:17 ET Modular Medical ( MODD ) -24% . Eloxx Pharmaceuticals ELOX -22% after Q1 earning release . LM Funding America ( LMFA ) -18% . Horizon Therapeutics Public Limited Company HZNP -18% reports FTC preparing suit to block Amgen de...
ALGS - Aligos Therapeutics and Xiamen Amoytop Biotech join hands for the treatment of liver diseases

2023-05-15 02:31:48 ET Clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, Aligos Therapeutics ( NASDAQ: ALGS ) enters research and development collaboration with Xiamen Amoytop Biotec...

ALGS - Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos' Oligonucleotide Platform for the Treatment of Liver Diseases

SOUTH SAN FRANCISCO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseas...

ALGS - Aligos Therapeutics GAAP EPS of -$0.53 misses by $0.05, revenue of $2.58M

2023-05-04 17:25:18 ET Aligos Therapeutics press release ( NASDAQ: ALGS ): Q1 GAAP EPS of -$0.53 misses by $0.05 . Revenue of $2.58M (+0.4% Y/Y). Cash, cash equivalents and investments totaled $103.5 million as of March 31, 2023, compared with $125.8 million as o...
Previous 10 Next 10